Tips for Pharmaceutical Manufacturing Scale-Up & Tech Transfer

Identifying early warning signals is vital to mitigate potential issues during the scale-up of manufacturing processes. Symptoms may vary but typically include:Click to read the full article.

Identifying the initial symptoms of yield loss is fundamental to effective troubleshooting. Typical signals might include:Click to read the full article.

Addressing Process Robustness and Yield Loss: A Root Cause Framework Manufacturing processes in the pharmaceutical industry are often plagued by challenges related to process robustness and yield loss. When deviations…

In the context of a recent scale-up for a sterile injectable product, operators noticed an increase in out-of-specification (OOS) results during potency testing. Manufacturing batch reports indicated variability in purity…

During a recent biopharmaceutical scale-up, operators observed several warning signs that prompted immediate investigation. Critical parameters related to yield and product quality were trending out of specification. Initially, the symptoms…

Recognizing early warning signs of process instability is critical in the high potency manufacturing environment. Common symptoms that might suggest a lack of process robustness include:Click to read the full…

The first step in addressing process robustness challenges is recognizing the symptoms or signals that indicate potential issues. Symptoms can vary but often include:Click to read the full article.

Identifying early warning signs is crucial for mitigating risks associated with mixing robustness during the scale-up phase. Common symptoms that might indicate issues with the mixing process include:Click to read…

Identifying symptoms of drying inefficiencies early allows for timely corrective measures. Common signals include:Click to read the full article.

Identifying the symptoms associated with compromised dissolution robustness is the first step in addressing potential issues in pharmaceutical manufacturing. Some common symptoms that may signal problems include:Click to read the…

During the transition to larger bioreactors, operators began observing several troubling trends:Click to read the full article.

During the recent scale-up of a monoclonal antibody (mAb) production process, several symptoms emerged that indicated potential process instability. Operators reported unusual fluctuations in process parameters, specifically during the purification…